Navigation Links
1st EMEA application filed for product using innovative intradermal microinjection system BD Soluvia
Date:2/13/2008

Franklin Lakes, NJ, USA (February 13, 2008) -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, has submitted the first application in Europe to deliver a vaccine using BD Soluvia, the innovative microinjection system developed by BD (Becton, Dickinson and Company). The submission for the first influenza vaccine using BD Soluvia has been accepted for review by the European Medicines Agency (EMEA).

Sanofi Pasteur conducted clinical trials on more than 7000 subjects to evaluate safety and the ability to generate an immune response of the novel intradermal (ID) influenza vaccine. Compared with intramuscular (IM) injection, ID delivery was shown to be especially effective in enhancing the immune response in the elderly1,2. Independently, BD conducted clinical trials involving more than 700 subjects and 3500 injections with BD Soluvia, and demonstrated that the system was safe and easy to use.3. Clinical testing showed that the BD microneedle is barely perceptible when it enters the skin and ensures the administration of the injected solution to the dermal layer irrespective of the subject s gender, age, ethnicity and body mass.4

BD Soluvia is a prefillable microinjection system that is integrated with a tiny BD microneedle. It has been proven to offer a simple, reliable method of delivery. While most vaccines are injected into the muscle, the BD microneedle allows the vaccine to be accurately delivered intradermally -- within the dermal layer of the skin. The dermal layer contains a dense network of lymphatic vessels feeding local lymph nodes, resulting in rapid and efficient access of the vaccine into the immune system. It also contains a high concentration of potent immune cells that play a key role to initiate the immune response following vaccination.

BD is committed to developing innovative solutions to advance drug delivery with pharmaceutical companies, and to meet the needs of healthcare professionals, said Philippe Laurent, Vice President, Medical Affairs, BD Medical V Pharmaceutical Systems. The BD Soluvia microinjection system is a breakthrough technology that is intuitive to use and allows accurate and consistent delivery of substances such as the flu vaccine into the dermal layer. We believe it has the potential to help address some of the important health challenges facing the world today, and embodies BD s purpose of helping all people live healthy lives.

We are delighted to have reached this landmark in development with our partner, sanofi pasteur, said Alex Conroy, President, BD Medical - Pharmaceutical Systems. In practical terms, the BD Soluvia microinjection system has the potential to increase patients acceptance of injections and enhance immunization practices. BD is deeply committed to continuing the development of BD Soluvia for the intradermal route of administration for use with infectious disease and emerging cancer vaccines.


'/>"/>
Contact: Alyssa Zeff
Alyssa_Zeff@bd.com
201-847-4358
Ruder Finn Public Relations
Source:Eurekalert

Related medicine news :

1. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
2. Investigational New Drug Application for Fat Melting Injections Cleared by the FDA
3. PreMD Provides Update on 510(k) Application for PREVU(x) POC
4. Mindray Selects Actel Low-Power Flash FPGAs for Demanding Medical Equipment Applications
5. Medical Services International Inc. Completes Testing for European Union (EU) Application
6. Pharsight Files Application for Nasdaq Capital Market Listing
7. PartsSource Awarded US Patent for PartsFinder(TM) Application
8. HealthCentral.com Launches Greeting Card Application on Facebook.com
9. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
10. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
11. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... ... As part of the nationwide Days of Remembrance effort led by the United ... persecution, Center for Medicine after the Holocaust (CMATH) announced that it will ... and Poland next week. , The Fourth Biennial CMATH Champions Trip to Germany and ...
(Date:4/24/2017)... ... , ... Today, Bright Pink , a national non-profit organization focusing on the prevention and ... , Bright Pink is proud to announce Katie Thiede as their new Chief Executive Officer. ... as Chairman of the Board and launched a national search to find a visionary ...
(Date:4/24/2017)... ... April 24, 2017 , ... Veteran Theresa James awoke to the ... life forever. , In “Healing Tears,” James depicts every parent’s worst nightmare, when her ... I began journaling conversations and situations throughout my divorce,” James said. “After the death ...
(Date:4/24/2017)... ... 2017 , ... The world-class designers of Happy Gadget Alert ... lifesaving device for the everyday use of parents worldwide. It is a lightweight, ... a child’s vital signs, and detect unusual symptoms or physical patterns. This innovative ...
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, a leading provider of ... that Kyle Allain has joined the company as Vice President and General Manager ... provider, payor and managed care solutions. , A seasoned executive with more ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
Breaking Medicine Technology: